Clinical Genetics of Haemoglobin and Development

Short version. The haemoglobinopathies are where molecular genetics began: Pauling et al. 1949 identified sickle cell anaemia as the first "molecular disease" by electrophoretic mobility, and Ingram 1957 showed at protein-sequence level that a single amino-acid substitution — β6 Glu→Val — explains the phenotype. Developmental genetics is where the same logic was scaled up to whole organisms: the Heidelberg saturation screens of Nüsslein-Volhard & Wieschaus 1980 uncovered the master regulators of body plan in Drosophila, and the same pathway components turned out to govern human development. This pillar page introduces the two subtopics; deeper coverage lives in the dedicated pages.

Why these two topics share a page

Classical clinical-genetics teaching pairs the haemoglobinopathies and the developmental signalling pathways for a reason. They are the two areas where the chain from gene → protein → cellular function → tissue phenotype → whole-organism disease can be told end-to-end in a way that students and trainees can remember. Sickle cell anaemia is the textbook example of how a single nucleotide substitution becomes a clinical phenotype; achondroplasia, holoprosencephaly, and the RASopathies are the textbook examples of how perturbing a developmental signalling pathway disturbs a body plan. The two case studies bracket the field: one is biochemistry made clinical, the other is embryology made clinical.

The historical arc also rhymes. Both fields were unlocked by an unfashionable methodological choice. Pauling chose to look at sickle cell haemoglobin as a protein on a gel rather than as a clinical syndrome; Nüsslein-Volhard and Wieschaus chose to mutate Drosophila embryos rather than to dissect a vertebrate. In each case, the technique came first and the clinical relevance was reverse-engineered later. Both projects were eventually recognised by Nobel Prizes — Pauling 1954 (Chemistry, partly for his protein work) and the 1995 Physiology or Medicine prize to Nüsslein-Volhard, Wieschaus, and Lewis for early embryonic development.

The first molecular disease: haemoglobin

In 1949, Linus Pauling, Harvey Itano, S. J. Singer, and Ibert Wells reported that haemoglobin from patients with sickle cell anaemia migrated differently on electrophoresis from haemoglobin in unaffected individuals (Pauling et al. 1949, Science 110:543). The paper named sickle cell anaemia as a "molecular disease" — the first time a clinical phenotype had been traced to an alteration of a specific protein. The molecular detail had to wait for sequencing methods. In 1957, Vernon Ingram showed by tryptic peptide fingerprinting that the difference between HbA and HbS was a single amino acid: glutamic acid at the sixth position of the β chain replaced by valine (Ingram 1957, Nature 180:326). The substitution — HBB:c.20A>T (p.Glu6Val) in modern HGVS notation — remains the textbook example of a Mendelian disease caused by a single point mutation.

The biology built outwards from there. The polymerisation of deoxygenated HbS in red cells, the rheological consequences for the microcirculation, the heterozygote-advantage explanation for the high allele frequency in regions of historical malaria endemism (Allison 1954), and the population genetics of the African, Mediterranean, Middle Eastern, and South Asian sickle cell and thalassaemia haplotypes are now standard teaching content. The thalassaemias — α and β — sit alongside the structural haemoglobinopathies as quantitative disorders of haemoglobin chain synthesis, with their own characteristic geographic distributions and genotype–phenotype correlations. The deep reference textbook for the field is Weatherall & Clegg, The Thalassaemia Syndromes (4th edition, 2001).

Modern haemoglobin genetics has two new strands. The first is the developmental switch from foetal haemoglobin (α₂γ₂, HbF) to adult haemoglobin (α₂β₂, HbA), regulated by the BCL11A repressor of the γ-globin genes and reactivable as a research strategy for sickle cell disease and β-thalassaemia. The second is gene therapy. Frangoul et al. 2021 (NEJM 384:252) reported the first patients treated with CTX001 / exa-cel (now Casgevy), a CRISPR-Cas9 disruption of the BCL11A erythroid enhancer that derepresses γ-globin and raises HbF. Casgevy received conditional approval from the UK MHRA in November 2023 and from the US FDA in December 2023 for sickle cell disease, and shortly thereafter for transfusion-dependent β-thalassaemia. We discuss this neutrally as research literature, not as a treatment recommendation.

For the full molecular and clinical detail of haemoglobin biology and the haemoglobinopathies, see haemoglobin biology and disorders.

Genes in development: signalling pathways

The genetics of development was opened up by a single experiment. Christiane Nüsslein-Volhard and Eric Wieschaus, working at the European Molecular Biology Laboratory in Heidelberg in the late 1970s, ran a saturation mutagenesis screen of Drosophila melanogaster embryos and looked at the resulting cuticle phenotypes for systematic disturbances of the body plan. Their 1980 paper (Nüsslein-Volhard & Wieschaus 1980, Nature 287:795) catalogued the gap, pair-rule, and segment-polarity genes. Edward Lewis's parallel work at Caltech on the bithorax complex established that homeotic genes specify the identity of body segments. The 1995 Nobel Prize in Physiology or Medicine to all three formalised what was already obvious to the field: the genes that build a fly build a vertebrate.

The pathways that fell out of those screens — Wingless / WNT, Hedgehog, Notch, Decapentaplegic / BMP / TGF-β, FGF, and the later Hippo pathway — form the core grammar of vertebrate development and a large fraction of human congenital malformation genetics. SHH heterozygous loss-of-function causes holoprosencephaly (Roessler et al. 1996, Nat Genet 14:357); NOTCH3 missense variants cause CADASIL; FGFR3 gain-of-function variants cause achondroplasia, hypochondroplasia, and thanatophoric dysplasia (see achondroplasia pedigree); the RASopathies (Noonan syndrome and its allelic and locus-related disorders) are caused by germline activating variants in components of the RAS–MAPK pathway (Roberts & Tartaglia 2010); FBN1 haploinsufficiency causes Marfan syndrome via dysregulated TGF-β signalling. The full survey is in genes in development.

The teaching point is that the same pathway behaves differently depending on dosage and timing. SHH haploinsufficiency causes a midline forebrain defect; SHH gain-of-function (via patched-1 loss) causes basal cell carcinoma and medulloblastoma (Foulkes et al. 2008, Nat Rev Cancer 8:851). The mechanism — haploinsufficiency, dominant negative, gain-of-function, or loss-of-function recessive — is part of the diagnostic signature, and it is what makes inheritance-pattern recognition from the pedigree informative even before molecular testing.

What this pair teaches the genetics student

Three lessons:

Genotype to phenotype is not magic. Sickle cell anaemia gives the cleanest worked example in human disease: a single nucleotide change, a single amino-acid substitution, a polymerisation defect under hypoxia, a microvascular consequence, a clinical syndrome.
The same gene products do different jobs in different contexts. The α-globin and β-globin loci illustrate developmental gene switching; SHH illustrates dosage-dependent and tissue-dependent biology; FGFR3 illustrates how the same gene yields a graded phenotypic series (hypochondroplasia, achondroplasia, thanatophoric dysplasia).
Inheritance patterns are diagnostic clues. Autosomal recessive transmission, parental consanguinity, ethnic-specific allele frequencies, sex-differential expression, and de novo dominant transmission are all visible in the pedigree before any DNA is sequenced. The pedigree is the integrating diagram. See pedigree chart and Mendelian inheritance calculator.

How Evagene fits

Evagene is an academic, research, and educational pedigree modelling platform. For the topics on this page, the platform is a teaching aid: students draw three- and four-generation pedigrees of fictional families to illustrate autosomal-recessive transmission of β-thalassaemia in a Mediterranean kindred, autosomal-dominant transmission of achondroplasia in an FGFR3-affected family, X-linked transmission of haemophilia, or de novo dominant patterns in a sporadic SHH holoprosencephaly case. The Mendelian inheritance calculator walks through carrier and offspring probabilities for these worked examples. The complex disease pedigree software page covers the recurrence-risk pages relevant to multifactorial congenital malformation. Outputs are illustrative and for educational and research purposes only; they are not clinical outputs and Evagene is not a medical device.

Subtopic pages

Haemoglobin biology and disorders — tetramer structure, HBB and HBA loci, sickle cell, α- and β-thalassaemia, HbF reactivation, gene therapy literature.
Genes in development — WNT, SHH, Notch, BMP/TGF-β, FGF, Hippo signalling and the human congenital malformations they cause, including the RASopathies and the skeletal dysplasias.

Key references

Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell anemia, a molecular disease. Science 1949; 110:543–548. PMID 15395398.
Ingram VM. Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature 1957; 180:326–328. PMID 13464827.
Allison AC. Protection afforded by sickle-cell trait against subtertian malarial infection. BMJ 1954; 1:290. PMID 13115700.
Nüsslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature 1980; 287:795–801. PMID 6776413.
Roessler E, Belloni E, Gaudenz K, et al. Mutations in the human Sonic Hedgehog gene cause holoprosencephaly. Nat Genet 1996; 14:357–360. PMID 8896572.
The Nobel Assembly. The Nobel Prize in Physiology or Medicine 1995. nobelprize.org.
Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. NEJM 2021; 384:252–260. PMID 33283989.
Foulkes WD. Inherited susceptibility to common cancers. Nat Rev Cancer 2008; 8:851–860 (Hedgehog medulloblastoma). PMID 18948956.

Frequently asked questions

Why is sickle cell anaemia called the first "molecular disease"?

Pauling et al. 1949 showed by electrophoresis that the haemoglobin from patients with sickle cell anaemia migrated differently from normal haemoglobin, naming it the first disease traced to an alteration of a specific protein. Ingram 1957 then identified the substitution at protein-sequence level — β6 Glu→Val.

What did the Nüsslein-Volhard–Wieschaus screen actually do?

A saturation mutagenesis screen of Drosophila embryos, looking at cuticle phenotypes to systematically catalogue genes that pattern the early embryo. The 1980 paper grouped them into gap, pair-rule, and segment-polarity classes, and the genes identified turned out to be vertebrate developmental regulators (Wingless / WNT, Hedgehog, Notch, etc.).

Why pair haemoglobin and developmental signalling on one page?

Both are flagship teaching cases of how molecular genetics scales from a nucleotide change to a clinical phenotype. Haemoglobin is the cleanest worked example for biochemistry; developmental signalling pathways are the cleanest worked example for embryology and congenital malformation genetics.

Is Casgevy / exa-cel a treatment recommendation?

No. We cite Frangoul et al. 2021 (NEJM 384:252) and the 2023 MHRA / FDA approvals neutrally as part of the research literature on γ-globin reactivation. Evagene is an educational platform; treatment decisions are made by clinicians with their patients.

What can a genetics student do with Evagene for these topics?

Draw fictional pedigrees that illustrate autosomal-recessive transmission of β-thalassaemia, autosomal-dominant achondroplasia, X-linked haemophilia, and de novo dominant SHH-associated holoprosencephaly. Use the Mendelian inheritance calculator to walk through carrier and offspring probabilities. Outputs are illustrative for teaching, not clinical.

Clinical genetics of haemoglobin and development